Product Description
Rifabutin is a derivative of rifamycin S with activity against mycobacteria including atypical organisms such as Mycobacterium avium and M. intracellulare, also referred to as Mycobacterium avium-intracellulare complex (MAC). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7521834/)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Colombia | Czech | Denmark | Dominican Republic | Finland | France | Germany | Greece | Hong Kong | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Luxembourg | Malta | Netherlands | New Zealand | Portugal | Russia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Georgia, Germany, Greece, Hungary, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 2: Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Tuberculosis
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BV100-006 | P2 |
Active, not recruiting |
Pneumonia, Ventilator-Associated |
2024-11-30 |
|
| BV100-004 | P1 |
Recruiting |
Healthy Volunteers |
2024-10-30 |
|
| BV100-008 | P1 |
Recruiting |
Healthy Volunteers |
2024-07-30 |
|
| 2022-002856-37 | P2 |
Active, not recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2024-05-25 |